Weight-Based Tranexamic Acid is More Effective in Reducing Postoperative Blood Loss Compared to a Fixed-Dose Regimen in Revision Hip Arthroplasty: A Comparative Study.
Chenchen Yang, Baochao Ji, Guoqing Li, Xiaogang Zhang, Boyong Xu, Asihaerjiang Maimaitiyiming, Li Cao
{"title":"Weight-Based Tranexamic Acid is More Effective in Reducing Postoperative Blood Loss Compared to a Fixed-Dose Regimen in Revision Hip Arthroplasty: A Comparative Study.","authors":"Chenchen Yang, Baochao Ji, Guoqing Li, Xiaogang Zhang, Boyong Xu, Asihaerjiang Maimaitiyiming, Li Cao","doi":"10.1016/j.arth.2025.07.058","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>The optimal dose of intravenous tranexamic acid (TXA) for surgical use remains uncertain. This study aimed to compare the postoperative blood loss, perioperative transfusion rate, in-hospital mortality, and complications between fixed-dose and weight-based TXA regimens in revision total hip arthroplasty (rTHA).</p><p><strong>Methods: </strong>We conducted a retrospective comparative analysis of 377 patients who underwent rTHA between March 2004 and March 2024, categorizing them into three groups based on the TXA regimen: (1) the no-TXA group; (2) the fixed-dose TXA group, who received one gram of intravenous TXA before skin incision, with an additional one gram of topical TXA; and (3) the weight-based TXA group, who received a weight-adjusted dose of 20 mg/kg/hour of intravenous TXA before skin incision, with an additional one gram of topical TXA. The maximal decrease in hemoglobin (Hb), perioperative transfusion rate, and incidence of in-hospital mortality and complications were recorded.</p><p><strong>Results: </strong>The maximal decrease in Hb levels was lower in the weight-based TXA group than in both the no TXA and fixed-dose TXA groups (27.8 versus 41.9 g/L, P < 0.001, and 27.8 versus 39.0 g/L, P < 0.001, respectively). However, it did not differ between the no-TXA and fixed-dose TXA groups. Both the fixed-dose and weight-based TXA groups had lower perioperative transfusion rates than the no-TXA group (P < 0.001). Additionally, the perioperative transfusion rate was lower in the fixed-dose TXA group than in the weight-based TXA group (P < 0.001). Changes in the dose of intravenous TXA did not significantly impact mortality or major complications in the three groups.</p><p><strong>Conclusion: </strong>Compared with fixed-dose TXA, a weight-based TXA dose was associated with less postoperative blood loss in rTHA without increasing the incidence of in-hospital mortality or major complications. Surgeons should consider implementing the weight-based TXA regimen in rTHA to effectively mitigate postoperative blood loss.</p>","PeriodicalId":51077,"journal":{"name":"Journal of Arthroplasty","volume":" ","pages":""},"PeriodicalIF":3.8000,"publicationDate":"2025-07-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Arthroplasty","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.arth.2025.07.058","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ORTHOPEDICS","Score":null,"Total":0}
引用次数: 0
Abstract
Background: The optimal dose of intravenous tranexamic acid (TXA) for surgical use remains uncertain. This study aimed to compare the postoperative blood loss, perioperative transfusion rate, in-hospital mortality, and complications between fixed-dose and weight-based TXA regimens in revision total hip arthroplasty (rTHA).
Methods: We conducted a retrospective comparative analysis of 377 patients who underwent rTHA between March 2004 and March 2024, categorizing them into three groups based on the TXA regimen: (1) the no-TXA group; (2) the fixed-dose TXA group, who received one gram of intravenous TXA before skin incision, with an additional one gram of topical TXA; and (3) the weight-based TXA group, who received a weight-adjusted dose of 20 mg/kg/hour of intravenous TXA before skin incision, with an additional one gram of topical TXA. The maximal decrease in hemoglobin (Hb), perioperative transfusion rate, and incidence of in-hospital mortality and complications were recorded.
Results: The maximal decrease in Hb levels was lower in the weight-based TXA group than in both the no TXA and fixed-dose TXA groups (27.8 versus 41.9 g/L, P < 0.001, and 27.8 versus 39.0 g/L, P < 0.001, respectively). However, it did not differ between the no-TXA and fixed-dose TXA groups. Both the fixed-dose and weight-based TXA groups had lower perioperative transfusion rates than the no-TXA group (P < 0.001). Additionally, the perioperative transfusion rate was lower in the fixed-dose TXA group than in the weight-based TXA group (P < 0.001). Changes in the dose of intravenous TXA did not significantly impact mortality or major complications in the three groups.
Conclusion: Compared with fixed-dose TXA, a weight-based TXA dose was associated with less postoperative blood loss in rTHA without increasing the incidence of in-hospital mortality or major complications. Surgeons should consider implementing the weight-based TXA regimen in rTHA to effectively mitigate postoperative blood loss.
背景:外科静脉注射氨甲环酸(TXA)的最佳剂量仍不确定。本研究旨在比较改良全髋关节置换术(rTHA)中固定剂量和基于体重的TXA方案的术后出血量、围手术期输血率、住院死亡率和并发症。方法:对2004年3月至2024年3月间377例rTHA患者进行回顾性比较分析,根据TXA方案将其分为三组:(1)无TXA组;(2)定剂量TXA组,皮肤切开前静脉注射1 g TXA,外加外用1 g TXA;(3)以体重为基础的TXA组,在皮肤切开前静脉注射20mg /kg/h的体重调整剂量的TXA,外加1克的局部TXA。记录两组患者血红蛋白(Hb)最大降幅、围手术期输血率、住院死亡率及并发症发生率。结果:以体重为基础的TXA组Hb水平的最大下降低于无TXA和固定剂量的TXA组(27.8对41.9 g/L, P < 0.001, 27.8对39.0 g/L, P < 0.001)。然而,在无TXA和固定剂量TXA组之间没有差异。固定剂量和体重为基础的TXA组围手术期输血率均低于无TXA组(P < 0.001)。此外,固定剂量的TXA组围手术期输血率低于基于体重的TXA组(P < 0.001)。静脉注射TXA剂量的变化对三组患者的死亡率和主要并发症没有显著影响。结论:与固定剂量的TXA相比,基于体重的TXA剂量与rTHA术后出血量较少相关,且未增加院内死亡率和主要并发症的发生率。外科医生应考虑在rTHA中实施基于体重的TXA方案,以有效减轻术后失血。
期刊介绍:
The Journal of Arthroplasty brings together the clinical and scientific foundations for joint replacement. This peer-reviewed journal publishes original research and manuscripts of the highest quality from all areas relating to joint replacement or the treatment of its complications, including those dealing with clinical series and experience, prosthetic design, biomechanics, biomaterials, metallurgy, biologic response to arthroplasty materials in vivo and in vitro.